Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMANKTO)

Drug Name
Vatreptacog alfa (activated) Drug Info
Synonyms NN-1731; NNC-0078-0000-0007; Recombinant factor VIIa analog with mutations V158D/E296V/M298Q (bleeding disorders), Novo Nordisk
Indication
Disease Entry ICD 11 Status REF
Bleeding disorder GA20-GA21 Phase 3 [1]
Cross-matching ID
TTD Drug ID
DMANKTO

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Coagulation factor VII (F7)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Factor viia DMZUW6P Hemophilia 3B10.0 Approved [3]
BAX-817 DMB147A Hemophilia 3B10.0 Phase 3 [4]
Activated recombinant FVII-albumin fusion protein DMKY9GI Hemophilia 3B10.0 Phase 2/3 [5]
Recombinant factor VIIa PEGylated liposomal DMY3TAD Factor VII deficiency 3B14 Phase 1/2 [3]
F-7TG DML4JXZ Hemophilia 3B10.0 Phase 1 [3]
Eptacog alfa DMAQYRL Hemophilia 3B10.0 Phase 1 [6]
CB-813 DMXQGKL Hemophilia 3B10.0 Phase 1 [7]
BAY 86-6150 DM6R3WC Hemophilia 3B10.0 Discontinued in Phase 2/3 [8]
RNAPc2 DME9V0I Colorectal cancer 2B91.Z Discontinued in Phase 2 [9]
Fucose DMAHMSV N. A. N. A. Investigative [10]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Coagulation factor VII (F7) TTF0EGX FA7_HUMAN Modulator [2]

References

1 ClinicalTrials.gov (NCT01392547) Efficacy and Safety of NNC 0078-0000-0007 in Patients With Congenital Haemophilia and Inhibitors. U.S. National Institutes of Health.
2 Recombinant factor VIIa analog (vatreptacog alfa [activated]) for treatment of joint bleeds in hemophilia patients with inhibitors: a randomized controlled trial. J Thromb Haemost. 2012 Jan;10(1):81-9.
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2363).
4 Clinical pipeline report, company report or official report of Baxter.
5 ClinicalTrials.gov (NCT01542619) A Safety and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor VIIa With Albumin (rVIIa-FP) in Healthy Male Volunteers. U.S. National Institutes of Health.
6 Recombinant factor VIIa (eptacog alfa): a review of its use in congenital hemophilia with inhibitors, acquired hemophilia, and other congenital bleeding disorders. BioDrugs. 2008;22(2):121-36.
7 Clinical pipeline report, company report or official report of Catalyst Biosciences.
8 Bayer HealthCare and Maxygen Announce Hematology Agreement. U.S. Securities and Exchange Commission. July 2, 2008.
9 rNAPc2 inhibits colorectal cancer in mice through tissue factor. Clin Cancer Res. 2009 Jan 1;15(1):208-16.
10 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.